OMNI

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

Retrieved on: 
Wednesday, April 10, 2024
FDA, American Academy, International, MIGS, American Journal, IOP, Patient, Intraocular pressure, Medicine, Lop, OMNI, Mercury (element), Vision science

OMNI facilitates a unique implant-free, ab interno procedure that comprehensively addresses the three primary areas of resistance in the conventional outflow pathway.

Key Points: 
  • OMNI facilitates a unique implant-free, ab interno procedure that comprehensively addresses the three primary areas of resistance in the conventional outflow pathway.
  • OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
  • The primary treatment goal for the high baseline IOP group (> 18mmHg) was IOP reduction, with a secondary goal to reduce medication burden.
  • The primary treatment goal for the low baseline IOP group (

Cogir Senior Living Expands SafelyYou to 36 Communities and into Assisted Living after Reducing the Number of Residents Falling by an Impressive 52%

Retrieved on: 
Tuesday, April 23, 2024
Mental Health, Technology, Seniors, Hospitals, Neurology, Health Technology, Managed Care, Consumer, Health, Artificial Intelligence, Acuity, Risk, Death, Partnership, OMNI, Organization, Senior living, Management

With SafelyYou’s proven success, Cogir is furthering the innovation’s reach across both communities and care levels, expanding to 36 communities, and now offering SafelyYou for assisted living as well as memory care.

Key Points: 
  • With SafelyYou’s proven success, Cogir is furthering the innovation’s reach across both communities and care levels, expanding to 36 communities, and now offering SafelyYou for assisted living as well as memory care.
  • Cogir began its partnership with SafelyYou to address resident falls—one of the toughest challenges in senior living—and improve resident outcomes.
  • Cogir is expanding SafelyYou into a segment of assisted living to better meet residents’ care needs and mitigate fall risk.
  • This technology allows us to be even better at serving our mission, delivering higher-quality care, and creating better experiences for residents at Cogir communities.”

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
IOP, Gland, Signs, Ciclosporin, Glaucoma, LHT, Wills Eye Hospital, ASCRS, BCEC, Patient, Telecanthus, Meibomian gland dysfunction, Doctor of Philosophy, MD, GEMINI, DED, OMNI, Signs and symptoms, Safety, Poster, Pharmaceutical industry

MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Key Points: 
  • OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma (“POAG”).
  • Lead author: Julio Echegoyen, MD, PhD
    Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation.
  • The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
  • Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Retrieved on: 
Thursday, March 7, 2024
ASPS, IOP, Research, Randomized controlled trial, OMNI, Growth, Ophthalmology, Telecanthus, Nature, Intraocular pressure, Safety, GAAP, Medicare, Patient, News, Webcast, Clinical trial, Uncertainty, Security (finance), LCD, Environment, Depreciation, Pharmaceutical industry

Reduced cash used to $6.4 million in the fourth quarter of 2023 compared to $10.0 million used in the third quarter of 2023, a decrease of 36%, and $14.8 million used in the fourth quarter of 2022, a decrease of 57%.

Key Points: 
  • Reduced cash used to $6.4 million in the fourth quarter of 2023 compared to $10.0 million used in the third quarter of 2023, a decrease of 36%, and $14.8 million used in the fourth quarter of 2022, a decrease of 57%.
  • Gross profit for the fourth quarter of 2023 was $16.0 million compared to $16.9 million in the same period in the prior year.
  • Gross margin for the fourth quarter of 2023 was 85%, compared to 82% in the same period in the prior year.
  • Sight Sciences' management team will host a conference call today, March 7, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Greenworks® Unveils Two New State-of-the-Art Facilities To Bolster Speed, Service, and Operations in North America

Retrieved on: 
Wednesday, February 21, 2024
Social media, Senior, OMNI, Investment, Commercial, Advertising, Warehouse

Opening March 1, 2024, the Greenworks® West Coast Warehouse and Service Center will provide swift distribution, plus a commercial service repair center.

Key Points: 
  • Opening March 1, 2024, the Greenworks® West Coast Warehouse and Service Center will provide swift distribution, plus a commercial service repair center.
  • The Greenworks® Ontario Canadian Headquarters and Warehouse, which opened last fall, includes the trilingual North America Customer Service Team, a sales showroom, repair center, state-of-the-art distribution center, and a photo and video studio.
  • "We're excited to announce the grand opening of our latest investments, which expands the Greenworks® footprint and business operations deeper into our commercial, direct-to-consumer, and retail partnerships," says Klaus Hahn, President of Greenworks® North America.
  • With a grand opening on March 1, 2024, the Greenworks® West Coast Warehouse and Service Center will revolutionize operations.

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

Retrieved on: 
Wednesday, February 14, 2024
Cataract, Glaucoma, Regulation, Research, OMNI, Peter Hancock (professor), Princess Alexandra Eye Pavilion, Surgeon, Entrepreneurship, CE marking, Patient, Pharmaceutical industry

"We believe the improved handle ergonomics, simplified viscoelastic preparation, and new cannula tip design will be invaluable to our European partners, so we are excited to launch the technology at the European Society of Cataract and Refractive Surgeons (“ESCRS”) Winter meeting this week in Frankfurt."

Key Points: 
  • "We believe the improved handle ergonomics, simplified viscoelastic preparation, and new cannula tip design will be invaluable to our European partners, so we are excited to launch the technology at the European Society of Cataract and Refractive Surgeons (“ESCRS”) Winter meeting this week in Frankfurt."
  • “The innovations in design of the Ergo-Series have the benefit of making the device even more intuitive to hold and operate.
  • The enhanced cannula tip can provide gentle, precise access to Schlemm’s canal and improved tactile feedback, giving the surgeon confidence at every step of the procedure.
  • I believe these improvements make OMNI even more accessible for surgeons treating all stages of open-angle glaucoma.”

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Retrieved on: 
Monday, January 8, 2024
Telecanthus, Ophthalmology, OMNI, Entrepreneurship, Glaucoma, Physician, Macs, Bank statement, Medicare, MIGS, Patient, CMS, Pharmaceutical industry

MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.
  • The Company’s cash and cash equivalents as of December 31, 2023, was approximately $138 million, compared to $144.5 million as of September 30, 2023.
  • The Company’s fourth quarter and full year 2023 financial results are preliminary and subject to the completion of the Company’s 2023 audit.
  • The Company expects to announce complete fourth quarter and full year 2023 financial results in March 2024.

ECOVACS Redefines Smart Home at CES 2024 with Revolutionary Whole Home Robotics Innovations

Retrieved on: 
Monday, January 8, 2024
Butter, OMNI, Family, Ecosystem, Bread, Collection, GOAT, W2, Movement, Robotics, Vacuum, Human, Freedom, Hobby, Streaking, Animal, LAS, RLM, COMBO, Safety, CES, Corel Linux, Intelligence, Algorithm, Relaxation

LAS VEGAS, Jan. 8, 2024 /PRNewswire/ -- At CES 2024,  ECOVACS is unveiling the future of whole home robotics, including revolutionary robots for floor-, air-, ceiling-, window-, and lawn- care. The DEEBOT X2 COMBO, a new iteration of the award-winning X2 OMNI, and the next-generation WINBOT W2 OMNI, showcase cutting-edge features and embody ECOVACS' core mission of 'Robotics for All'. X2 COMBO is the first DEEBOT that is Matter-ready, and comes with upgraded hands-free capabilities and precision for cleaning floors, drapes, ceilings, and more, ushering users into a fully automated era of whole-house cleaning. W2 OMNI now comes with an all-in-one station, making it the most portable robotic window cleaner on the market. Homeowners no longer need to bear the burden of uncleaned homes – ECOVACS takes care of it all, alleviating worries and stressors. Taking hands-free cleaning outdoors, ECOVACS' all-new robot lawn mower - GOAT GX 600 - will maintain lawns and manicure grass in the US, beginning Spring 2024. GX 600 uses similar technology DEEBOTs have to make automated lawn care easy - no boundary setting necessary; just press go and GX 600 will mow. ECOVACS is showcasing the all-new DEEBOT X2 COMBO, WINBOT W2 OMNI, and GOAT GX 600, along with several other innovative smart home robots - including the AIRBOT Z2 air purification robot - at CES 2024 in Las Vegas from January 9-12, 2024, in the Venetian Expo, Halls A-D - booth 52632.

Key Points: 
  • LAS VEGAS, Jan. 8, 2024 /PRNewswire/ -- At CES 2024, ECOVACS is unveiling the future of whole home robotics, including revolutionary robots for floor-, air-, ceiling-, window-, and lawn- care.
  • Taking hands-free cleaning outdoors, ECOVACS' all-new robot lawn mower - GOAT GX 600 - will maintain lawns and manicure grass in the US, beginning Spring 2024.
  • For 25 years, ECOVACS has pioneered smart home cleaning solutions with its market-leading robotics.
  • "Our dedication to reshaping the smart home cleaning experience extends far beyond technological innovation," emphasized Vice Chairman of ECOVACS Group and CEO of ECOVACS ROBOTICS, David Qian.

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Retrieved on: 
Friday, December 8, 2023
IOP, OMNI, GEMINI, Ophthalmology, ANSI, Intraocular pressure, Patient, Safety, Pharmaceutical industry

MENLO PARK, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the acceptance for publication in Clinical Ophthalmology of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI® Surgical System technology (“OMNI”). Publication is currently expected by December 31, 2023.

Key Points: 
  • GEMINI 2, a prospective, multi-center, medication washout trial designed to obtain 36-month follow-up for patients treated in the original 12-month GEMINI trial, has been completed.
  • Favorable results demonstrate sustained and clinically significant intraocular pressure (“IOP”) reduction of greater than 20% and clinically significant IOP lowering medication reduction at 36 months.
  • The prospective 3-year clinical outcomes in the GEMINI 2 trial confirm and extend the previously published 12-month data from the original GEMINI trial.
  • In the original GEMINI study, at 12 months, OMNI plus cataract surgery achieved a mean IOP reduction of 8.2 mmHg (-34%).

Next Round of the Skode Program Launches to Spark the Development of 6 New Indigenous Tourism Experiences in Ontario

Retrieved on: 
Friday, December 15, 2023
Tourism, Organization, TIL, OMNI

AUNDECK OMNI KANING, ON, Dec. 15, 2023 /CNW/ - Indigenous Tourism Ontario (ITO) and the Tourism Innovation Lab (TIL) have launched the 4th edition of the Skode Program, an initiative to spark new Indigenous tourism ideas and experiences that authentically represent, celebrate and promote Indigenous culture and communities in Ontario.

Key Points: 
  • AUNDECK OMNI KANING, ON, Dec. 15, 2023 /CNW/ - Indigenous Tourism Ontario (ITO) and the Tourism Innovation Lab (TIL) have launched the 4th edition of the Skode Program, an initiative to spark new Indigenous tourism ideas and experiences that authentically represent, celebrate and promote Indigenous culture and communities in Ontario.
  • Indigenous tourism entrepreneurs, businesses and organizations are encouraged to apply and share the fire within their hearts.
  • The Skode program is a collaboration of innovative work between Indigenous Tourism Ontario and the Tourism Innovation Lab.
  • "We are thrilled to announce this fourth round of the Skode Program in collaboration with Indigenous Tourism Ontario.